CN117835977A - Tead抑制剂的给药方案 - Google Patents

Tead抑制剂的给药方案 Download PDF

Info

Publication number
CN117835977A
CN117835977A CN202280057415.5A CN202280057415A CN117835977A CN 117835977 A CN117835977 A CN 117835977A CN 202280057415 A CN202280057415 A CN 202280057415A CN 117835977 A CN117835977 A CN 117835977A
Authority
CN
China
Prior art keywords
cancer
tead
treatment
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280057415.5A
Other languages
English (en)
Chinese (zh)
Inventor
E·沙波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN117835977A publication Critical patent/CN117835977A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280057415.5A 2021-09-01 2022-08-30 Tead抑制剂的给药方案 Pending CN117835977A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163239506P 2021-09-01 2021-09-01
US63/239,506 2021-09-01
PCT/IB2022/058130 WO2023031798A1 (en) 2021-09-01 2022-08-30 Dosing regimen for a tead inhibitor

Publications (1)

Publication Number Publication Date
CN117835977A true CN117835977A (zh) 2024-04-05

Family

ID=83355146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280057415.5A Pending CN117835977A (zh) 2021-09-01 2022-08-30 Tead抑制剂的给药方案

Country Status (11)

Country Link
US (1) US20240358720A1 (https=)
EP (1) EP4395768A1 (https=)
JP (1) JP2024532325A (https=)
KR (1) KR20240055021A (https=)
CN (1) CN117835977A (https=)
AU (1) AU2022340987A1 (https=)
CA (1) CA3225444A1 (https=)
IL (1) IL309246A (https=)
MX (1) MX2024002566A (https=)
TW (1) TW202327579A (https=)
WO (1) WO2023031798A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156404A1 (en) * 2015-10-15 2017-04-19 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4030233B1 (en) 2019-09-18 2025-05-07 Ningbo Sunny Opotech Co., Ltd. Periscopic camera module and electronic device
UY39129A (es) 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CA3205726A1 (en) 2021-01-25 2022-07-28 Alfredo C. Castro Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer

Also Published As

Publication number Publication date
IL309246A (en) 2024-02-01
US20240358720A1 (en) 2024-10-31
MX2024002566A (es) 2024-03-20
EP4395768A1 (en) 2024-07-10
JP2024532325A (ja) 2024-09-05
WO2023031798A1 (en) 2023-03-09
KR20240055021A (ko) 2024-04-26
AU2022340987A1 (en) 2024-01-18
CA3225444A1 (en) 2023-03-09
TW202327579A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
KR102860817B1 (ko) 트라디피턴트에 의한 치료 방법
AU2006315512B2 (en) Administration of an mTOR inhibitor to treat patients with cancer
JP2012515184A (ja) 大腸がんの治療方法
JP2017519019A (ja) ｍｄｍ２阻害剤の間欠投与
TWI866427B (zh) 雌激素受體降解劑之給藥方案
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
CN117835977A (zh) Tead抑制剂的给药方案
WO2018099423A1 (zh) 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途
EP4087572A1 (en) Combination therapy for treating cancer
WO2024046332A1 (zh) 医药组合物及其用途
TW201235038A (en) Sensitizer, kit and use for cancer therapy
CN111617081A (zh) 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途
US12551471B2 (en) ABT-751 and ionizing radiation
CN111195250A (zh) 西达本胺联合dice的应用及联合药物
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
HK40127185A (zh) 雌激素受体降解剂的给药方案
WO2024131727A1 (zh) 一种内磺酰胺化合物治疗胆道癌的用途
CN121401261A (zh) 喹诺林化合物治疗甲状腺癌的用途
US20090239872A1 (en) Treatment of mesothelioma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination